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Subgroup analysis showed that higher doses of factor Xa inhibitors (odds ratio 2.5, 95% CI 1.4 to 4.5), but not lower doses, increased risk for major bleeding (P = 0.02 for interaction).
Conclusion
In patients having total knee or hip replacement, oral direct factor Xa inhibitors reduced symptomatic deep venous thrombosis compared with low-molecular-weight heparin but did not differ for mortality, pulmonary embolism, or bleeding. 
Commentary
VTE is an important complication of major orthopedic surgery. Advances in surgical technique, early ambulation, and early hospital discharge coupled with safer and more effective pharmacologic agents have reduced the risk for symptomatic VTE (DVT or PE). Rates of symptomatic VTE of 15% to 30% after TKR or THR before 1980 have been reduced to 1% to 2% in some recent studies (1, 2) through improved surgical techniques, earlier ambulation, and medical and mechanical thromboprophylaxis. This is an attractive market for newer anticoagulant drugs, and numerous studies now document their relative safety and efficacy compared with older anticoagulants. The duration of anticoagulation after TKR or THR has also been explored in clinical trials with patients receiving shortterm (≤ 14 d) or extended (> 21 d) anticoagulant prophylaxis (3).
Most patients included in the well-done meta-analysis by Neumann and colleagues received prophylaxis for ≤ 14 days. Any potential benefit of extended prophylaxis was not reported. The authors note that oral factor Xa inhibitors reduce risk for symptomatic VTE but that higher doses of these drugs are associated with an increased risk for bleeding. Communication with the authors indicated that there was no interaction between dose of factor Xa inhibitors and DVT, PE, or mortality. Accordingly, there is no evidence to support the use of higher doses.
This class of drugs represents a viable and important option for patients receiving VTE prophylaxis after orthopedic surgery. The convenience of oral administration will be a significant advantage for many patients. Acceptance by patients and physicians will likely be influenced by the cost of the drugs and insurance reimbursement policies. 
Question
How do oral direct factor Xa inhibitors compare with low-molecular-weight heparin (LMWH) for prophylaxis of venous thromboembolism (VTE) in patients having total knee replacement (TKR) or total hip replacement (THR)?
Review scope
Included studies compared oral direct factor Xa inhibitors with LMWH in patients who had TKR or THR and reported any of mortality, symptomatic deep venous thrombosis (DVT), nonfatal pulmonary embolism (PE), major bleeding, or bleeding leading to reoperation. 22 RCTs (n = 32 159, 45% to 73% women, mean age 58 to 68 y) met the selection criteria. Drugs assessed were rivaroxaban (8 RCTs); edoxaban (4 RCTs); apixaban (4 RCTs); YM150 (2 RCTs); and betrixaban, razaxaban, TAK442, and LY517717 (1 RCT each). 11 RCTs included patients having THR, 10 included patients having TKR, and 1 included patients having either THR or TKR. Prophylaxis duration ranged from 5 to 39 days, and follow-up was < 14 days in 9 RCTs, 30 to 70 days in 12 RCTs, and ≤ 90 days in 1 RCT. Overall study quality was moderate for trials contributing to the major bleeding outcome and high for RCTs contributing to other outcomes, as assessed by the Grading of Recommendations Assessment, Development, and Evaluation approach.
Review methods
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Main results
Meta-analysis showed that factor Xa inhibitors reduced symptomatic DVT more than LMWH; groups did not differ for mortality, nonfatal PE, major bleeding, or bleeding leading to reoperation (Table) .
